Pharming Group N.V. (OTCPK:PHGUF) Full Year 2021 Earnings Conference Call March 17, 2022 9:00 AM ET Company Participants Sijmen Vries - Executive Director and Chief Executive Officer Jeroen Wakkerman - Chief Financial Officer Anurag Relan - Chief Medical Officer Conference Call Participants Hartaj Singh - Oppenheimer & Co Joe Pantginis - H.C. Wainright Alex Cogut - Kempen Christian Glennie - Stifle Operator Hello and welcome to Pharming’s Full Year 2021 Results call. My name is Jordan and I’ll be coordinat ...

Pharming Group N.V. (OTCPK:PHGUF) Q3 2021 Results Conference Call October 28, 2021 7:30 AM ET Company Participants Sijmen de Vries - CEO Dr. Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Hartaj Singh - Oppenheimer & Co. Joe Pantginis - H.C. Wainright Simon Scholes - First Berlin Sijmen de Vries Thank you very much. Good morning, good afternoon. Welcome to our nine months 2021 results call. I will be happy taking you through the call with a couple of my colleagues, ...

Pharming Group N.V. (OTCPK:PHGUF) Q2 2021 Earnings Conference Call August 5, 2021 1:00 PM ET Company Participants Sijmen De Vries - Chief Executive Officer Jeroen Wakkerman - Chief Financial Officer Conference Call Participants Joe Pantginis - Wainwright Alex Cogut - Kempen Christian Glennie - Stifel Sijmen De Vries Good afternoon, ladies and gentlemen. I'm sitting here with Chief Financial Officer, Jeroen Wakkerman to take you through the half year results 2021. But before I do that, next slide, please, I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...